SCHEMBL4777540

SCHEMBL4777540

COC(=O)c1ccccc1N(Cc1cccc(Cl)c1Cl)S(C)(=O)=O

nearest known ligand 0.65

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
POLB P06746 3/20 0.54
MCOLN3 Q8TDD5 1/20 0.54
KMT2A Q03164 3/20 0.52
LMNA P02545 1/20 0.47
MAPT P10636 1/20 0.47
MAPK1 P28482 1/20 0.45
L3MBTL1 Q9Y468 1/20 0.42
NPSR1 Q6W5P4 1/20 0.41
MEN1 O00255 2/20 0.41
ALDH1A1 P00352 3/20 0.41
PDE3B Q13370 1/20 0.41
PDE3A Q14432 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
HSD17B10 Q99714 1/20 0.41
TP53 P04637 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4767671 0.83 MAPT (0.51) POLBMCOLN3KMT2ALMNAMAPT
SCHEMBL4767773 0.81 LMNA (0.49) POLBMCOLN3KMT2ALMNAMAPT
SCHEMBL4777409 0.80 ALDH1A1 (0.51) POLBMCOLN3KMT2ALMNAMAPT
SCHEMBL4771011 0.79 LMNA (0.49) POLBMCOLN3KMT2ALMNAMAPT
SCHEMBL12513035 0.79 L3MBTL1 (0.61) POLBMCOLN3KMT2ALMNAL3MBTL1
SCHEMBL4773380 0.75 LMNA (0.42) POLBMCOLN3KMT2ALMNAMAPT
SCHEMBL18460409 0.74 POLB (0.54) POLBMCOLN3KMT2AMAPTMEN1
SCHEMBL4774743 0.72 ALDH1A1 (0.60) POLBKMT2ALMNAMAPTL3MBTL1
SCHEMBL4768135 0.72 MAPT (0.49) POLBKMT2ALMNAMAPTL3MBTL1
SCHEMBL4777497 0.72 MAPT (0.49) POLBKMT2ALMNAMAPTL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1942888-A2 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS Cytokinetics, Inc. (US) 2008-07-16 EP claimed
US-20070135435-A1 Certain chemical entities, compositions, and methods CYTOKINETICS, INCORPORATED 2007-06-14 US claimed
WO-2007056078-A2 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS CYTOKINETICS, INC. (US) 2007-05-18 WO claimed
EP-1942888-A2 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS Cytokinetics, Inc. (US) 2008-07-16 EP disclosed
US-20070135435-A1 Certain chemical entities, compositions, and methods CYTOKINETICS, INCORPORATED 2007-06-14 US disclosed
WO-2007056078-A2 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS CYTOKINETICS, INC. (US) 2007-05-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070135435-A1 Certain chemical entities, compositions, and methods KIF5B, KIF2C, PLK1 POLB 292/4885MCOLN3 1462/4885KMT2A 1501/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.